Skip to content
Tyrogenex's lead compound screening

Tyrogenex's lead compound screening

Reagents and Biosimilars for Wet Age-Related Macular Degeneration Research

  • Clia Kits
  • Equipments
  • Isotypes
  • Reagents
  • Peptides
  • RNA
  • Ria Kits
  • Test Kits
  • Recombinant Proteins
  • Equipments
  • Exosomes
  • Gels
  • Biology Cells
  • Assay Kits
  • NATtrol
  • biosimilars definition
  • biosimilars iqvia
  • biosimilars pdf
  • biosimilars act
  • biosimilars msd
  • Discontinuation of biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving sustained clinical remission or low disease activity during the IFX-SIRIUS STUDY I (the IFX-SIRIUS STUDY II): Study protocol for an interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments
  • Contact Us
The Importance of Countering Biosimilar Disparagement and Misinformation

The Importance of Countering Biosimilar Disparagement and Misinformation

biosimilar limited use in some health systems for biosimilars are not well understood by many health professionals and patients. This knowledge gap is exacerbated by

A Clinical Review of Biosimilars Approved in Oncology

A Clinical Review of Biosimilars Approved in Oncology

Objective: To summarize and review the clinical data from the Food and Drug Administration (FDA) biosimilars approved for use in the treatment of cancer and

Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn’s disease using real world evidence in Thailand

Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn’s disease using real world evidence in Thailand

Objective: This study aimed to analyze the cost-effectiveness and biosimilar infliximab compared with conventional therapy in fireproof moderate to severe Crohn’s disease (CD) in Thailand.Materials

Rituximab Biosimilar Prevents Poor Outcomes of Microscopic Polyangiitis and Granulomatosis with Polyangiitis as Effectively as Rituximab Originator

Rituximab Biosimilar Prevents Poor Outcomes of Microscopic Polyangiitis and Granulomatosis with Polyangiitis as Effectively as Rituximab Originator

Objective: There are no extensive study to compare the effectiveness between the originator rituximab (Mabthera®) and its biosimilar (Truxima®) for microscopic polyangiitis (MPA) and granulomatosis

Reporting of quality attributes in scientific publications presenting biosimilarity assessments of (intended) biosimilars: a systematic literature review

Reporting of quality attributes in scientific publications presenting biosimilarity assessments of (intended) biosimilars: a systematic literature review

Last year, more than 46 unique biosimilars have been approved by the EMA and / or US-FDA following patent expiry of the reference product. Biosimilars

Recent Posts

  • The Importance of Countering Biosimilar Disparagement and Misinformation
  • A Clinical Review of Biosimilars Approved in Oncology
  • Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn’s disease using real world evidence in Thailand
  • Rituximab Biosimilar Prevents Poor Outcomes of Microscopic Polyangiitis and Granulomatosis with Polyangiitis as Effectively as Rituximab Originator
  • Reporting of quality attributes in scientific publications presenting biosimilarity assessments of (intended) biosimilars: a systematic literature review
May 2022
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
« Aug    

Categories

  • Antibodies
  • Assay Kits
  • Biology Cells
  • cDNA
  • Clia Kits
  • Culture Cells
  • Devices
  • DNA
  • DNA Templates
  • DNA Testing
  • Elisa Kits
  • Enzymes
  • Equipments
  • Exosomes
  • Gels
  • Isotypes
  • Medium & Serums
  • NATtrol
  • Panel
  • Particles
  • PCR
  • Pcr Kits
  • Peptides
  • Reagents
  • Recombinant Proteins
  • Ria Kits
  • RNA
  • Test Kits
  • Uncategorized
  • Vector & Virus
  • Western Blot

Tags

biosimilars 101 biosimilars 2019 biosimilars 2020 biosimilars act biosimilars amgen biosimilars book biosimilars ce biosimilars chemo biosimilars def biosimilars definition biosimilars drug biosimilars ema biosimilars fda biosimilars ibd biosimilars image biosimilars india biosimilars iqvia biosimilars list biosimilars msd biosimilars news biosimilars pdf biosimilars ppt biosimilars uk exosomes 5g exosomes and chf exosomes and coronavirus exosomes and ed exosomes and ms exosomes and ra reagents that break double bonds reagents undercity reagents used for pcr reagents usp reagents vendor reagents vendor orgrimmar reagents vendor tb reagents vendor uc recombinant proteins biotechnology recombinant proteins definition recombinant proteins drug recombinant proteins examples recombinant proteins ppt recombinant proteins production recombinant proteins sds page gel recombinant proteins technology

Pages

  • Contact Us
  • Discontinuation of biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving sustained clinical remission or low disease activity during the IFX-SIRIUS STUDY I (the IFX-SIRIUS STUDY II): Study protocol for an interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments
  • Distributors

Categories

  • Antibodies
  • Assay Kits
  • Biology Cells
  • cDNA
  • Clia Kits
  • Culture Cells
  • Devices
  • DNA
  • DNA Templates
  • DNA Testing
  • Elisa Kits
  • Enzymes
  • Equipments
  • Exosomes
  • Gels
  • Isotypes
  • Medium & Serums
  • NATtrol
  • Panel
  • Particles
  • PCR
  • Pcr Kits
  • Peptides
  • Reagents
  • Recombinant Proteins
  • Ria Kits
  • RNA
  • Test Kits
  • Uncategorized
  • Vector & Virus
  • Western Blot

Recent Posts

  • The Importance of Countering Biosimilar Disparagement and Misinformation
  • A Clinical Review of Biosimilars Approved in Oncology
  • Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn’s disease using real world evidence in Thailand
  • Rituximab Biosimilar Prevents Poor Outcomes of Microscopic Polyangiitis and Granulomatosis with Polyangiitis as Effectively as Rituximab Originator
  • Reporting of quality attributes in scientific publications presenting biosimilarity assessments of (intended) biosimilars: a systematic literature review

Tags

biosimilars 101 biosimilars 2019 biosimilars 2020 biosimilars act biosimilars amgen biosimilars book biosimilars ce biosimilars chemo biosimilars def biosimilars definition biosimilars drug biosimilars ema biosimilars fda biosimilars ibd biosimilars image biosimilars india biosimilars iqvia biosimilars list biosimilars msd biosimilars news biosimilars pdf biosimilars ppt biosimilars uk exosomes 5g exosomes and chf exosomes and coronavirus exosomes and ed exosomes and ms exosomes and ra reagents that break double bonds reagents undercity reagents used for pcr reagents usp reagents vendor reagents vendor orgrimmar reagents vendor tb reagents vendor uc recombinant proteins biotechnology recombinant proteins definition recombinant proteins drug recombinant proteins examples recombinant proteins ppt recombinant proteins production recombinant proteins sds page gel recombinant proteins technology
All Rights Reserved 2020
Proudly powered by WordPress | Theme: Opus Masonry by Aki Themes.